Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact.
With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
In today’s dynamic pharmaceutical landscape, having a high level of strategic alignment and the flawless execution of this strategy is crucial for life sciences companies aiming to establis
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.